Barclays PLC Has $260,000 Position in Zura Bio Limited (NASDAQ:ZURA)

Barclays PLC increased its stake in shares of Zura Bio Limited (NASDAQ:ZURA) by 777.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 64,061 shares of the company’s stock after purchasing an additional 56,757 shares during the quarter. Barclays PLC’s holdings in Zura Bio were worth $260,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Geode Capital Management LLC grew its stake in shares of Zura Bio by 70.6% during the third quarter. Geode Capital Management LLC now owns 912,625 shares of the company’s stock worth $3,706,000 after buying an additional 377,545 shares during the last quarter. Sphera Funds Management LTD. acquired a new stake in shares of Zura Bio during the 3rd quarter valued at $2,999,000. State Street Corp grew its position in Zura Bio by 47.5% during the 3rd quarter. State Street Corp now owns 395,059 shares of the company’s stock worth $1,604,000 after acquiring an additional 127,300 shares during the last quarter. Braidwell LP acquired a new position in Zura Bio in the 3rd quarter worth about $10,040,000. Finally, MetLife Investment Management LLC bought a new position in Zura Bio in the third quarter valued at about $111,000. 61.14% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently issued reports on ZURA. Leerink Partners assumed coverage on Zura Bio in a research note on Monday, November 4th. They issued an “outperform” rating and a $15.00 price objective for the company. HC Wainwright reissued a “neutral” rating and set a $5.00 target price on shares of Zura Bio in a report on Tuesday, December 24th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zura Bio in a research note on Wednesday, December 11th. Leerink Partnrs raised shares of Zura Bio to a “strong-buy” rating in a research note on Monday, November 4th. Finally, Chardan Capital decreased their price objective on Zura Bio from $14.00 to $12.00 and set a “buy” rating for the company in a report on Friday, November 8th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Zura Bio has a consensus rating of “Buy” and an average target price of $15.80.

Zura Bio Stock Performance

Zura Bio stock opened at $1.77 on Tuesday. The firm has a 50 day moving average price of $2.63 and a two-hundred day moving average price of $3.49. Zura Bio Limited has a 52-week low of $1.76 and a 52-week high of $6.35.

Zura Bio (NASDAQ:ZURA) last announced its earnings results on Thursday, November 7th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12). Equities analysts expect that Zura Bio Limited will post -0.65 earnings per share for the current fiscal year.

Insider Transactions at Zura Bio

In other Zura Bio news, Director Parvinder Thiara sold 1,001,633 shares of the stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $2.73, for a total transaction of $2,734,458.09. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 22.10% of the company’s stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.